Reviewers discussed new and conventional therapies for lupus nephritis and the prospect of precision medicine.
Your search for ESKD returned 6 results
Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.
The systematic review and meta-analysis included a broad range of patients with and without chronic kidney disease.
Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.
MK-2060 is an investigational monoclonal antibody designed to inhibit the activation of Factor XI and its ability to activate downstream proteins.
Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.